WESTMINSTER, Colo., November 18, 2025--(BUSINESS WIRE)--TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for ...
Hosted on MSN
TriSalus reaffirms 50% revenue growth target while advancing TriNav platform and product launches
CEO Mary Szela reported strong third quarter results, highlighting revenue of $11.6 million, a 57% increase year-over-year and 3% sequential growth. She noted continued expansion of the TriNav ...
DENVER, June 04, 2025--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our ...
DENVER, November 07, 2024--(BUSINESS WIRE)--TriSalus Life Sciences ® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to ...
DENVER & SALT LAKE CITY--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided ...
– Data published in Current Medical Research and Opinion provide a comparison of the TriNav Infusion System vs. standard drug delivery and show the ability of TriNav to successfully treat sicker, ...
(RTTNews) - TriSalus Life Sciences, Inc. (TLSI) has unveiled the TriNav FLX Infusion System, a new addition to its TriNav portfolio. The latest system enhances trackability and flexibility, allowing ...
Expanded Patient Access: The TriNav LV Infusion System is tailored for larger vessels (3.5-5.0 mm), increasing the number of patients eligible for TriSalus' proprietary Pressure-Enabled Drug Delivery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results